Placing
ThromboGenics NV, which is developing treatments for ophthalmic and vascular diseases and cancer, has announced that it has raised €42 million through a private placement of 2.6 million new shares at €16 per share.
Patrik De Haes, CEO of Leuven-based ThromboGenics, said, “I am very pleased that we have raised this additional funding from a broad range of Belgian and international institutional investors. Our significantly improved financial position will enable us to advance our innovative product portfolio, particularly our lead product, microplasmin, which is currently in a Phase III clinical trial programme for eye disorders.
“The funds will also enable ThromboGenics to commercialise microplasmin, a key step in our plans to become a profitable, integrated company focused on cutting edge ophthalmic medicines.”
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
